PREDICTING BONE METASTASIS IN PROSTATE CANCER PATIENTS: VALUE OF PROSTATE SPECIFIC ANTIGEN AT SARDJITO HOSPITAL, YOGYAKARTA

By Ahmad Sulaiman Lubis

Objective
Prostate cancer 90 % of patients die Prostate cancer strong predilection to spread to the bones Serum prostate specific antigen (PSA) biomarker

to diagnose and monitor prostate cancer

Technetium-99m methylene diphosphate (Tc-99m MDP) whole body bone scintigraphy diagnostic procedure for bone metastasis

Material and Methods

Male patients with prostate cancer retrospectively analyzed All of the subjects received bone scintigraphy and serum PSA concentration measured at Sardjito

Hospital, Yogyakarta
The proper cut-off value statistical analysis

Results
83 male patients with prostate cancer 55 patients (66 %) bone metastases were confirmed by scintigraphic A serum PSA concentration of 17,65 ng/ml gave

the best sensitivity (78,33%) and specificity (65,21%)

Positive predictive value85,45 % Negative predictive value 53,57 %

Conclusion
A cut-off value of PSA 17,65 ng/mlmetastatic bone disease in prostate cancer patients at Sardjito Hospital, Yogyakarta Patients with prostate cancer,PSA level

< 17,65 ng/ml and without any skeletal symptoms

bone scintigraphy (-)

THANK YOU